Skip to main content
FDA Priority Review Voucher Programs
Content coming soon. In the meantime, please reach out with any questions or for assistance.
Related Services
Rare Pediatric Disease Designation
Strategic support for FDA Rare Pediatric Disease Designation and Priority Review Vouchers.
Learn moreOrphan Drug Designations
Expert guidance for FDA and EMA orphan drug designation applications.
Learn moreRegulatory Designations
Strategic support for FDA and EMA expedited program designations.
Learn moreRelated Insights
FDA Regulatory StrategySeptember 10, 2024
Will the FDA's Rare Pediatric Disease Designation Priority Review Voucher Program Be Renewed?
Analysis of the RPD PRV Program's impact and likelihood of renewal, including RareMoon's perspective on this critical regulatory pathway for rare pediatric disease treatments.
Read: Will the FDA's Rare Pediatric Disease Designation Priority Review Voucher Program Be Renewed?Regulatory UpdateJuly 25, 2025
This Week's Update to the FDA's Commissioner's National Priority Voucher (CNPV) Pilot Program
Explore the FDA's new CNPV Pilot Program, a Commissioner-led initiative offering expedited review for therapies addressing critical public health priorities outside existing PRV pathways.
Read: This Week's Update to the FDA's Commissioner's National Priority Voucher (CNPV) Pilot Program